Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist—protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Introduction: Antipsychotic medication is widely associated with dysmetabolism including obesity and type 2 diabetes, cardiovascular-related diseases and early death. Obesity is considered the single most important risk factor for cardiovascular morbidity and mortality. Interventions against antipsychotic-associated obesity are limited and insufficient. Glucagon-like peptide-1 (GLP-1) receptor agonists are approved for the treatment of type 2 diabetes, but their bodyweight-lowering effects have also been recognised in patients with non-diabetes. The primary endpoint of this trial is weight loss after 3 months of treatment with a GLP-1 receptor agonist (exenatide once weekly) in patients with non-diabetic schizophrenia with antipsychotic-associated obesity. Secondary endpoints include physiological and metabolic measurements, various psychopathological and cognitive measures, and structural and functional brain MRI. Methods and analysis: 40 obese patients with schizophrenia or schizoaffective disorder treated with antipsychotic drugs will be randomised to subcutaneous injection of exenatide once weekly (2 mg) or placebo for 3 months, adjunctive to their antipsychotic treatment. Ethics and dissemination: The trial has been approved by the Danish Health and Medicines Authority, the National Committee on Health Research Ethics and the Danish Data Protection Agency. Trial participation presupposes theoral and written patient informed consent. An external, independent monitoring committee (Good Clinical Practice Unit at Copenhagen University Hospital) will monitor the study according to the GCP Guidelines. Trial data, including positive, negative and inconclusive results, will be presented at national and international scientific meetings and conferences. Papers will be submitted to peer-reviewed journals. Trial registration: ClinicalTrials.gov identifier: NCT01794429 ; National Committee on Health Research Ethics project number: 36378; EudraCT nr: 2012-005404-17; The Danish Data Protection Agency project number: RHP-2012-027.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lingjærde, O., Ahlfors, U. G., Bech, P., Dencker, S. J., & Elgen, K. (1987) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1987.tb10566.x · Cited by 1,705
Keefe, R. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2003.09.011 · Cited by 1,573
Morosini, P. L., Magliano, L., Brambilla, L., Ugolini, S., & Pioli, R. (2000) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2000.101004323.x · Cited by 1,097 · cited 1×
“Global assessment of functioning and the Personal and Social Performance Scale (PSP) will be used to assess the patient’s overall level of functioning.(29) The International Physical Activity Questionnaire will be employed to evaluate physical activity.”
MethodDrucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070 · cited 2×
“2 SDs based on Drucker et al.(32) In a priori Student t test (two-sided) with significance level α of 0.”
MethodInfluentialVilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970
Self-citationGlucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851
on behalf of the NN8022-1807 Investigators, Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.158 · Cited by 757 · cited 1×
“ports that they facilitate weight loss in obese patients with and without diabetes.(12) 13 Recently, we suggested the GLP-1 receptor agonist”
BackgroundHunter, K., & Hölscher, C. (2012) · BMC Neuroscience · doi:10.1186/1471-2202-13-33 · Cited by 504
Severe Mental Illness and Risk of Cardiovascular Disease
Newcomer, J. W., & Hennekens, C. H. (2007) · JAMA · doi:10.1001/jama.298.15.1794 · Cited by 433 · cited 1×
“Antipsychotic-associated obesity is a major and unresolved clinical problem due to its strong association to increased cardiovascular morbidity and premature death among patients with schizophrenia and other mental illnesses.(2) 4 33 34 Moreover, obesity is associated with accelerated brain deterioration, cognitive de…”
BackgroundWilleumier, K. C., Taylor, D. V., & Amen, D. G. (2011) · Obesity · doi:10.1038/oby.2011.16 · Cited by 223 · cited 1×
“Finally, using single photon emission CT imaging the cerebral blood flow (CBF) in frontal cortex has been shown to be negatively associated with increased body weight in patients with non-psychiatric obesity.(20) Interestingly, the frontal CBF is also compromised in normal weight patients with schizophrenia.”
MethodHoang, U., Stewart, R., & Goldacre, M. J. (2011) · BMJ · doi:10.1136/bmj.d5422 · Cited by 222
McClean, P. L., Gault, V. A., Harriott, P., & Hölscher, C. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.12.023 · Cited by 193
Caemmerer, J., Correll, C. U., & Maayan, L. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.03.017 · Cited by 182
Ebdrup, B. H., Knop, F. K., Ishøy, P. L., Rostrup, E., Fagerlund, B., Lublin, H., & Glenthøj, B. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-92 · Cited by 34 · cited 2×
“therapy as a potential treatment strategy for patients with schizophrenia and obesity.(10) In a subsequent case report we provided the first clinical evidence in support of this idea.”
BackgroundSelf-citation
Research works printed but not linked: 21
- Mukundan A Faulkner G Cohn T . Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database Syst Rev 2010;(8):CD006629. · DOI · Paper page
- 10.1007/s11892-010-0112-8 · DOI
- 10.1111/j.1467-789X.2009.00570.x · DOI · Paper page
- Megna, 2011, Obesity in adults with serious and persistent mental illness: a review of postulated mechanisms and current interventions, Ann Clin Psychiatry, 23, 131, 10.1177/104012371102300207 · DOI · Paper page
- 10.1161/CIRCULATIONAHA.109.192644 · DOI · Paper page
- 10.1016/j.maturitas.2009.11.026 · DOI
- Holst JJ . The physiology of glucagon-like peptide 1. Physiol Rev 2007;87:1409–39. · DOI · Paper page
- 10.1176/appi.ajp.2013.12101344 · DOI
- Bomba, 2013, Exenatide promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals, Cell Death, 4, e612, 10.1038/cddis.2013.139 · DOI · Paper page
- 10.2165/11635890-000000000-00000 · DOI · Paper page
- 10.1093/schbul/13.2.261 · DOI · Paper page
- Fastenau, 1996, Development and preliminary standardization of the ‘extended complex figure test’ (ECFT), J Clin Exp Neuropsychol, 18, 63, 10.1080/01688639608408263 · doi:10.1080/01688639608408263
- Bright P Jaldow E Kopelman MD . The National Adult Reading Test as a measure of premorbid intelligence: a comparison with estimates derived from demographic variables. J Int Neuropsychol Soc 8:847–54. · DOI · Paper page
- Bjorner JB Thunedborg K Kristensen TS . The Danish SF-36 Health Survey : translation and preliminary validity studies 1998;51:991–9. · DOI · Paper page
- 10.1249/01.MSS.0000078924.61453.FB · DOI · Paper page
- 10.1186/1475-2891-12-75 · DOI · Paper page
- Colton, 2006, Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states, Prev Chronic Dis, 3, A42
- 10.1371/journal.pone.0055176 · DOI · Paper page
- Kolotkin, 2008, Impact of obesity on health-related quality of life in schizophrenia and bipolar disorder, Obesity (Silver Spring), 16, 749, 10.1038/oby.2007.133 · DOI · Paper page
- Faulkner, 2010, Interventions to reduce weight gain in schizophrenia (review), Schizophr Bull, 33, 654, 10.1093/schbul/sbm022 · DOI · Paper page
- 10.1136/bmj.c869 · DOI · Paper page
Cited by
Protective role of IGF-1 and GLP-1 signaling activation in neurological dysfunctions
Bhalla, S., Mehan, S., Khan, A., & Rehman, M. U. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104896 · Cited by 108
Ishøy, P. L., Knop, F. K., Broberg, B. V., Bak, N., Andersen, U. B., Jørgensen, N. R., Holst, J. J., Glenthøj, B. Y., & Ebdrup, B. H. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12795 · Cited by 102
Self-citationGlucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes
Mayfield, K., Siskind, D., Winckel, K., Russell, A. W., Kisely, S., Smith, G., & Hollingworth, S. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881115625496 · Cited by 49
Ebdrup, B. H., Broberg, B. V., Ishøy, P. L., Bak, N., Andersen, U. B., Jørgensen, N. R., Holst, J. J., Knop, F. K., & Glenthøj, B. Y. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13204 · Cited by 35
“treatment (exenatide 2 mg once-weekly or placebo) in antipsychotictreated schizophrenia patients with obesity.(1) Recently, we published”
BackgroundSelf-citationEriksson, R., Broberg, B. V., Ishøy, P. L., Bak, N., Andersen, U. B., Jørgensen, N. R., Knop, F. K., & Ebdrup, B. H. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00781 · Cited by 26
Self-citation
Metadata
- Authors
- Ishøy, P. L., Knop, F. K., Broberg, B. V., Baandrup, L., Fagerlund, B., Jørgensen, N. R., Andersen, U. B., Rostrup, E., Glenthøj, B. Y., & Ebdrup, B. H.
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2014-01
- Volume
- 4
- Issue
- 1
- Pages
- e004158
- ISSN
- 2044-6055 (ISSN-L)
- OpenAlex
- W2149821062
- Cited by
- 24
- References
- 14
- FWCI
- 2.69
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.